Compare ICMB & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ICMB | BOLD |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 36.5M |
| IPO Year | 2013 | 2024 |
| Metric | ICMB | BOLD |
|---|---|---|
| Price | $1.31 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 45.3K | ★ 127.7K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 21.74% | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $0.96 |
| 52 Week High | $3.12 | $1.68 |
| Indicator | ICMB | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 30.88 | 50.05 |
| Support Level | $1.28 | $1.40 |
| Resistance Level | $2.99 | $1.55 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 18.00 | 34.15 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.